Cargando…
Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state
Many types of human cancers are being treated with small molecule ATP-competitive inhibitors targeting the kinase domain of receptor tyrosine kinases. Despite initial successful remission, long-term treatment almost inevitably leads to the emergence of drug resistance mutations at the gatekeeper res...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
National Academy of Sciences
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974468/ https://www.ncbi.nlm.nih.gov/pubmed/36791110 http://dx.doi.org/10.1073/pnas.2213090120 |